# ALBAN (NCT03799835)

> Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03799835
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: UNICANCER
- Conditions: Bladder Cancer
- Interventions: BCG; Atezolizumab
- Enrollment: 517
- Primary outcome: Event-Free Survival

## Commentary we found

- X threads: 40
- YouTube: 23
- Podcasts: 19

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=alban-nct03799835

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03799835", "email": "<work email>"}; the inbox owner confirms by the emailed link.